Latest Regulatory Uncertainty News

PEXA Group has dismissed any undisclosed information behind its recent share price drop, attributing market moves to a preliminary IPART pricing consultation paper.

Energy Transition Minerals Ltd (ETM) confronts unexpected uncertainty as Greenlandic authorities signal potential non-extension of the Kvanefjeld exploration licence, disrupting planned 2026 activities and intensifying ongoing legal disputes.

iCandy Interactive has announced plans for Lemon Sky Studios to pursue a US IPO on the NYSE American, targeting a US$15 million capital raise, while highlighting strategic pivots in AI and blockchain markets.

Sequoia Financial Group has postponed its interim dividend payment to mid-May as it finalises the sale of InterPrac and awaits ASX guidance on a potential shareholder meeting.

AdAlta’s subsidiary AdCella has completed its first Joint Development Committee meeting with Shanghai Cell Therapy Group, advancing the development of the CAR-T therapy BZDS1901 with potential timeline acceleration and reduced regulatory risks.

St Barbara Limited has satisfied all conditions for its strategic Lingbao Gold Group transaction, targeting completion on 1 April 2026 with an anticipated A$0.5 billion gain on sale. Meanwhile, the Kumul Minerals deal awaits final PNG government approvals but is expected to close concurrently.

Sequoia Financial Group has agreed to sell its financial planning arm InterPrac to Conquest Investment Partners for $50,000, following a strategic review that exposed significant challenges and asset write-downs.

The Takeovers Panel has received a formal review application challenging its recent decision on Humm Group Limited, signaling potential further scrutiny of the corporate governance dispute.

Aura Energy has postponed its strategic transaction for the Häggån project due to an ongoing Swedish government inquiry into alum shale mining and current market conditions, while retaining full ownership and commitment to the project.

AJ Lucas Group Limited has swung to a $38.9 million half-year profit, buoyed by a significant UK settlement and improved Australian drilling operations despite revenue pressures.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.

Lynas Rare Earths Ltd has reported a striking half-year turnaround with a 1260% surge in net profit, underpinned by rising rare earth prices and strategic expansions. The company also completed a major equity raise to fuel its ambitious Towards 2030 growth plan.